Description
(AWP Alliance News) - Sandoz narrowed its 2026 net sales growth forecast to 5-6% at constant currencies, from mid-to-high single-digit growth. It raised its core EBITDA margin guidance to 23-23.5%, replacing a forecast for an increase of around 100 basis points from 21.7% in 2025. Short-term biosimilar supply constraints in Europe and International, alongside tougher-than-expected temporary market conditions in Germany, prompted the sales revision.
A more favorable sales mix and stronger operational performance supported the margin upgrade. Third-quarter net sales rose 5% at constant currencies, with biosimilar sales up 17%.
https://www.publicnow.com/view/D1214B2FA6D5D9FB867B1C870FDCAF228D55A693…
Disclaimer: This news brief was created using generative artificial intelligence. Sandoz Group AG published the original content used to generate this news brief via EQS News on October 28, 2026, and is solely responsible for the information contained therein.
